Skip to content

Study · Case report or series · n = 1 · 2026

1 result

Dramatic Improvement of Treatment-Refractory Prurigo Nodularis Following Initiation of Semaglutide: A Case Report.

Fougerousse AC

Clinical, cosmetic and investigational dermatology28 Aug 2026

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a man with treatment-refractory prurigo nodularis, a dramatic and progressive clinical improvement followed semaglutide initiation for obesity with no change to background treatment.

    In plain wordsIn one man with stubborn prurigo nodularis, the skin condition improved a great deal after he started semaglutide for obesity.

    Outcome
    Not applicableClinical improvement of treatment-refractory prurigo nodularis
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Following initiation of semaglutide for obesity, and with no change to his background PN treatment, a dramatic and progressive clinical improvement was observed.
    1 context sentence
    Summary · context
    We report the case of a 64-year-old man with severe, treatment-refractory PN who had failed multiple lines of therapy over four years, including potent topical corticosteroids, dupilumab, and methotrexate.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.